Fresenius Medical Care AG (FMS) Stock Price & Analysis
Fresenius Medical Care AG (FMS) closed at USD 22.23 on Thursday, October 22, 2026, up 3.11% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 21.56; the Oct 22, 2026 session ranged USD 21.57–22.24 on volume of 1,117,468 shares. Market capitalization is $11.83B, with a 52-week range of USD 20.02–27.4 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:24 UTC.
Also available as compact Markdown for AI agents: nexqual.com/FMS.md
Key facts (FMS)
- 2 of 80 tracked superinvestors hold FMS (13F, Q2 2026): 0 new, 0 added, 1 reduced, 1 unchanged.
- Analysts: Sell (mean 3.57 on a 1–5 scale) (7 analysts), mean target USD 23.82 (range 17.31–37.87).
- Total return with dividends: 1Y -14.1% vs S&P 500 +14.9%; 5Y -27.7% vs S&P 500 +80.3%.
- Next earnings: 2026-11-03, EPS estimate USD 0.53, revenue estimate $4.92B.
Superinvestors (SEC 13F-HR, Q2 2026) (FMS)
2 of 80 tracked investors hold FMS. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Richard Pzena | Pzena Investment Management | 1.00% | $339M | Reduced -0.4% |
| Dodge & Cox Funds | Dodge & Cox | 0.05% | $86.5M | Unchanged |
Analysts (FMS)
Consensus Sell (mean 3.57 on a 1–5 scale), 7 analysts; mean target USD 23.82 (low 17.31, high 37.87).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-12 | Truist Securities | Target lowered | Hold | $25 → $24 |
| 2026-08-06 | Bernstein | Target raised | Market Perform | $25.5 → $25.8 |
Total return (dividends reinvested) (FMS)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | -14.1% | -27.7% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -14.1% | -6.3% |
| Volatility (annualized) | 30.8% | 31.2% |
| Max drawdown | -25.9% (Oct 2025→May 2026) | -62.1% (Oct 2021→Oct 2022) |
Companies that name FMS in their SEC reports
| Relationship to FMS | Company | Filing | Sentence |
|---|---|---|---|
| partner | Cytosorbents Corp (CTSO) | 10-K Mar 30, 2026 | “These partners include Fresenius Medical Care AG, B.” |
| partner | Humacyte, Inc. (HUMA) | 10-K Mar 27, 2026 | “our expectations regarding our strategic partnership with Fresenius Medical Care Holdings, Inc. ("Fresenius Medical Care") to sell, market and distribute our 6 millimeter ATEV for certain specified indications and in specified markets, if approved by regulatory authorities;” |
FMS analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.53 | $0.56 | -6.4% | $4.92B | 2 |
| Next quarter (ends Dec 2026) | $0.53 | $0.61 | -13.7% | $5.20B | 2 |
| Current fiscal year (ends Dec 2026) | $2.07 | $2.46 | -15.8% | $19.49B | 4 |
| Next fiscal year (ends Dec 2027) | $2.65 | $3.17 | -16.4% | $20.15B | 5 |
FMS options: expected move
Options price a move of about ±14.8% (±$3.30) by Nov 20, 2026, which includes earnings on Nov 3, 2026.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 54.1% | ±14.8% |
| Jan 15, 2027 | 84 | 47.9% | ±18.6% |
| Apr 16, 2027 | 175 | 35.1% | ±19.2% |
30-day implied volatility 43.5% vs 34.5% realized over the last 30 trading days. Put/call ratio (volume) 25. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:24 UTC)
| Price | USD 22.23 |
|---|---|
| Change | ▲ 3.11% (up) |
| Previous Close | USD 21.56 |
| Open | USD 21.59 |
| Day Range | USD 21.57 – 22.24 |
| 52-Week Range | USD 20.02 – 27.4 |
| Volume | 1,117,468 shares |
| Market Cap | $11.83B |
| Exchange | NYQ |
Technical Analysis (FMS)
Nexqual's technical model rates FMS "SELL" based on 2 bullish and 4 bearish signals across 127 daily candles, as of October 23, 2026 at 09:24 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 52.76 (neutral) |
| vs SMA50 | Below (USD 22.5) |
| MACD | -0.22 (negative) |
Analyst Ratings (FMS)
Wall Street analysts rate FMS "Sell" based on 7 analysts, with a mean price target of USD 23.82 (range USD 17.31–37.87), per Nexqual as of October 23, 2026 at 09:24 UTC.
| Consensus Rating | Sell |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 23.82 |
| High Target | USD 37.87 |
| Low Target | USD 17.31 |
| Buy / Hold / Sell | 1 / 3 / 3 |
Earnings (FMS)
| Next Earnings Date | 2026-11-03 |
|---|---|
| EPS Estimate | USD 0.53 |
| Revenue Estimate | $4.92B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.57 vs est 0.5 ▲ beat |
| 2026-03-31 | USD 0.46 vs est 0.5 ▼ miss |
| 2025-12-31 | USD 0.72 vs est 0.55 ▲ beat |
| 2025-09-30 | USD 0.55 vs est 0.5 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:24 UTC.
Financials & Fundamentals (FMS)
| Total Revenue | $19.43B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +1.40% |
| Gross Margin | +26.35% |
| Operating Margin | +10.77% |
| Profit Margin | +4.83% |
| ROE | +8.52% |
| Debt / Equity | 0.81 |
| Current Ratio | 1.07 |
| Total Cash | $1.06B |
| Total Debt | $10.98B |
Source: Nexqual, October 23, 2026 at 09:24 UTC.
Financial Health Score (FMS)
Nexqual rates Fresenius Medical Care AG's overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 09:24 UTC.
| Growth | Mixed — Revenue +1.5% YoY (annual), slow |
|---|---|
| Profitability | Solid — Gross margin 26%, operating 11% (last 12 months) |
| Balance Sheet | Mixed — EUR 1.06B cash vs EUR 11.0B debt |
| Cash Flow | Solid — Operating cash flow EUR 2.83B (TTM) |
| Efficiency | Mixed — ROE 9%, ROA 4.0% |
Ownership (FMS)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +9.87% |
| Shares Outstanding | 532.22M |
| Float | 397.12M |
Source: Nexqual, October 23, 2026 at 09:24 UTC.
Leadership (FMS)
Fresenius Medical Care AG is led by Joseph E. Turk, CEO of Care Enablement & Member of Management Board, per Nexqual as of October 23, 2026 at 09:24 UTC.
| CEO of Care Enablement & Member of Management Board | Joseph E. Turk |
|---|---|
| CFO & Member of the Management Board | Martin Fischer |
| Member of the Management Board, Global Head of Legal,Compliance & Human Resources and Labor Director | Jorg Haring |
| Senior Vice President of Corporate Communications & Governmental Affairs | Joachim Weith |
| Senior Vice President of Research & Development | Gail-Suzanne Brown |
Major Backers & Investors (FMS)
Notable institutional backers of Fresenius Medical Care AG include Pzena Investment Management LLC, Morgan Stanley, Dodge & Cox Inc., according to Nexqual as of October 23, 2026 at 09:24 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Pzena Investment Management LLC | 3.06% |
| Morgan Stanley | 0.89% |
| Dodge & Cox Inc. | 0.78% |
| Fiduciary Management, Inc. | 0.6% |
| Brandes Investment Partners L.P. | 0.39% |
| Millennium Management | 0.32% |
| Todd Asset Management LLC | 0.27% |
| Liberty All Star Equity Fund | 0.23% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.19% |
Source: Nexqual, October 23, 2026 at 09:24 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| DVA | DaVita Inc. | USD 186.1 | ▲ 5.25% |
| EHC | Encompass Health Corporation | USD 126.01 | ▲ 4.6% |
| UHS | Universal Health Services, Inc. | USD 188.13 | ▲ 2.88% |
| ENSG | The Ensign Group, Inc. | USD 178.35 | ▲ 2.88% |
| PACS | PACS Group, Inc. | USD 47.5 | ▲ 1.58% |
| CHE | Chemed Corp | USD 520.15 | ▲ 1.72% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:24 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt